October 09, 2025 a 01:00 pm
STE: Analysts Ratings - STERIS plc
STERIS plc, a global leader in infection prevention, continues to garner attention with consistent analyst ratings. Despite some fluctuations, the overall sentiment remains strong due to the company's solid market position and diverse product offerings. The healthcare sector's growth and STERIS's innovation in sterilization technologies support a positive outlook.
Historical Stock Grades
The most recent analyst ratings for STERIS plc as of October 2025 reveal a stable sentiment. Analysts have given the stock 3 Strong Buy, 2 Buy, and 3 Hold recommendations. Notably, there are no Sell or Strong Sell ratings, indicating a lack of negative sentiment toward the stock. The score distribution reflects a steady confidence in the company's performance.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 2 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The analyst sentiment for STERIS plc has shown notable consistency over recent months. The total number of ratings has remained stable, reflecting sustained interest from analysts. The following trends have been observed:
- The number of Strong Buy ratings decreased slightly, indicating cautious optimism.
- Hold ratings have shown a minor increase, suggesting some analysts adopt a wait-and-see approach.
- Overall, no Sell or Strong Sell recommendations suggest a positive market perception.
Percentage Trends
Analyzing the percentage distribution of analyst ratings gives further insights into market sentiment shifts:
- Strong Buy recommendations have declined slightly from previous periods, moving from a high of 57% in July to 43% in October 2025.
- The percentage of Buy ratings decreased, showing caution among investors.
- An increase in Hold ratings indicates a balanced perspective on STERIS's market position.
- The absence of Sell recommendations continues to exhibit confidence in STERIS's business model.
Over the last year, the most significant shift was observed in the Hold category, marking more conservative outlooks among some analysts.
Latest Analyst Recommendations
Recent recommendations from leading analysts provide further insight into STERIS's current standing:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-08 | Overweight | Overweight | Morgan Stanley |
| 2025-07-22 | Overweight | Overweight | Keybanc |
| 2025-07-15 | Overweight | Equal Weight | Morgan Stanley |
| 2025-05-19 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-05-16 | Market Outperform | Market Outperform | JMP Securities |
Analyst Recommendations with Change of Opinion
Analyzing opinions where there was a distinct change in ratings helps assess sentiment shifts:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-15 | Overweight | Equal Weight | Morgan Stanley |
| 2024-10-24 | Overweight | Neutral | Piper Sandler |
| 2023-04-14 | Neutral | Overweight | Piper Sandler |
| 2023-04-13 | Neutral | Overweight | Piper Sandler |
| 2022-09-23 | Hold | Buy | Needham |
Interpretation
From the analysis, it is clear that STERIS plc holds a stable market perception. The consistent level of Strong Buy and Buy recommendations, with no Sell ratings, suggests confidence in the company's performance and strategic direction. However, the slight increase in Hold ratings may indicate a cautious optimism, likely due to external economic factors and market competition. The stability in analyst opinions reflects a well-regarded market position and low perceived risk.
Conclusion
In summary, STERIS plc has maintained a generally positive sentiment among analysts, with consistent ratings supporting its market position. The company's strategic focus on infection prevention products and services provides a competitive edge, although slight caution is evident in the increase of Hold ratings. The absence of Sell recommendations and stable Overweight assessments highlight minimal perceived risk. STERIS remains a viable option for investors seeking exposure in the healthcare sector, balancing growth opportunities and sector-specific risks.